Nesrin Damla Eyupoglu1, Ezgi Caliskan Guzelce1, Aylin Acikgoz2, Esra Uyanik3, Bodil Bjørndal4, Rolf K Berge4,5, Asbjørn Svardal4, Bulent Okan Yildiz1,6. 1. Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey. 2. Department of Nutrition and Dietetics, Hacettepe University School of Health Sciences, Ankara, Turkey. 3. Department of Gynecology and Obstetrics, Hacettepe University School of Medicine, Ankara, Turkey. 4. Department of Clinical Sciences, University of Bergen, Bergen, Norway. 5. Department of Heart Disease, Haukeland University Hospital, Bergen, Norway. 6. Division of Endocrinology and Metabolism, Hacettepe University School of Medicine, Ankara, Turkey.
Abstract
OBJECTIVES: Polycystic ovary syndrome (PCOS) is associated with an increased cardiometabolic risk that might not necessarily translate into adverse cardiovascular outcome later in life. Recently, alterations in gut microbial composition have been reported in the syndrome. Microbiota-dependent metabolite trimethylamine N-oxide (TMAO) and its precursors are closely linked with development of atherosclerotic cardiovascular disease, independently of traditional risk factors. We aimed to assess whether TMAO and its precursors are altered in PCOS and to determine potential impact of treatment on these metabolites. DESIGN: Prospective study. PATIENTS: Twenty-seven overweight/obese patients with PCOS and 25 age- and BMI-matched healthy control women. MEASUREMENTS: At baseline, fasting serum TMAO and its precursors were measured after a 3-day standardized diet. Patients received 3-month OC therapy along with general dietary advice after which all measurements were repeated. RESULTS: Patients had higher total testosterone (T) and free androgen index (FAI) whereas whole-body fat mass, fasting plasma glucose, insulin and lipids were similar between the groups. PCOS group showed significantly higher serum levels of TMAO and its precursors; choline, betaine and carnitine. TMAO and choline showed correlations with T. After 3 months of OC use, TMAO and its precursors significantly decreased along with reductions in BMI, T and FAI. CONCLUSIONS: This study reports for the first time that TMAO and its precursors are elevated in PCOS which might contribute to increased cardiometabolic risk of the syndrome and that short-term OC use along with lifestyle intervention is associated with reduction of these microbiome-dependent metabolites.
OBJECTIVES:Polycystic ovary syndrome (PCOS) is associated with an increased cardiometabolic risk that might not necessarily translate into adverse cardiovascular outcome later in life. Recently, alterations in gut microbial composition have been reported in the syndrome. Microbiota-dependent metabolite trimethylamine N-oxide (TMAO) and its precursors are closely linked with development of atherosclerotic cardiovascular disease, independently of traditional risk factors. We aimed to assess whether TMAO and its precursors are altered in PCOS and to determine potential impact of treatment on these metabolites. DESIGN: Prospective study. PATIENTS: Twenty-seven overweight/obesepatients with PCOS and 25 age- and BMI-matched healthy control women. MEASUREMENTS: At baseline, fasting serum TMAO and its precursors were measured after a 3-day standardized diet. Patients received 3-month OC therapy along with general dietary advice after which all measurements were repeated. RESULTS:Patients had higher total testosterone (T) and free androgen index (FAI) whereas whole-body fat mass, fasting plasma glucose, insulin and lipids were similar between the groups. PCOS group showed significantly higher serum levels of TMAO and its precursors; choline, betaine and carnitine. TMAO and choline showed correlations with T. After 3 months of OC use, TMAO and its precursors significantly decreased along with reductions in BMI, T and FAI. CONCLUSIONS: This study reports for the first time that TMAO and its precursors are elevated in PCOS which might contribute to increased cardiometabolic risk of the syndrome and that short-term OC use along with lifestyle intervention is associated with reduction of these microbiome-dependent metabolites.
Authors: Beza Tayachew; Heidi Vanden Brink; Yesenia Garcia-Reyes; Haseeb Rahat; Angelo D'Alessandro; Daniel N Frank; Charles E Robertson; Lori Silveira; Megan Kelsey; Laura Pyle; Melanie Cree-Green Journal: Front Physiol Date: 2022-06-21 Impact factor: 4.755
Authors: Natalia Arias; Silvia Arboleya; Joseph Allison; Aleksandra Kaliszewska; Sara G Higarza; Miguel Gueimonde; Jorge L Arias Journal: Nutrients Date: 2020-08-05 Impact factor: 5.717